Acasti Pharma Inc. (ACST)
Symbol Info
Listed Symbol ACST
Name Acasti Pharma Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2019-03-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.71
Price Info
21 Day Moving Average $1.9962
21 Day EMA $2.054730
50 Day Moving Average $2.0132
50 Day EMA $1.900780
200 Day EMA $1.372350
200 Day Moving Average 1.219390
52 Week High $2.95
52 Week Low $0.56
52 Week Change $272.002800
Alpha -0.002004
Beta 1.3237
Standard Deviation 0.280499
R2 0.026401
Periods 60
Share Information
10 Day Average Volume 925,459
20 Day Average Volume 1,207,698
30 Day Average Volume 1,434,022
50 Day Average Volume 2,391,881
Outstanding Shares 85,177,262
Float Shares 85,177,262
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 19
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 187,823
Institute Holdings Percent 3.500000
Institute Sold Previous 3 Months 66,861
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $-0.0300002
7 Day Percent Change -1.40%
21 Day Price Change $0.2399999
21 Day Percent Change 12.83%
30 Day Price Change $0.2799999
30 Day Percent Change 15.30%
Month To Date Price Change $0.2400
Month To Date Percent 12.83%
90 Day Price Change $1.100000
90 Day Percent Change 108.91%
Quarter To Date $0.970000
Quarter To Date Percent 85.09%
180 Day Price Change $1.040000
180 Day Percent Change 97.20%
200 Day Price Change $1.030000
200 Day Percent Change 95.37%
Year To Date $1.278100
Year To Date Percent 153.64%
Profile
Description Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. Its only operating segment being the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.
Details
Issue Type CS
Market Cap $179,724,023
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 84,817,745
CEO Janelle D'Alvise
Employees 28
Last Audit UE
Classification
CIK 0001444192
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 545, Promenade du Centropolis
Suite 100
Laval, QC H7T 0A3
Website http://www.acastipharma.com
Facisimile +1 450 686-2505
Telephone +1 438 399-7114
Email ACST@crescendo-ir.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $159,001,404
Price To Sales -
Price To Free Cash -6.4
PE High Last 5 Years -
Price To Book 65.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 65.9
Financial Strength
Total Debt To Equity 0.5
Int Coverage -152.6
Current Ratio 1.6
Leverage Ratio 5.0
Quick Ratio 1.6
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -170.8
Return On Equity -1,006.68
Return On Capital -756.24
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACST
Acasti Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.